Elicio Therapeutics, Inc. (ELTX)
2.84
-0.16
(-5.33%)
USD |
NASDAQ |
Aug 28, 16:00
2.865
+0.02
(+0.88%)
After-Hours: 20:00
Elicio Therapeutics Cash from Operations (Quarterly) : -8.165M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.165M |
| March 31, 2026 | -11.64M |
| December 31, 2025 | -6.797M |
| September 30, 2025 | -11.09M |
| June 30, 2025 | -8.95M |
| March 31, 2025 | -10.12M |
| December 31, 2024 | -8.744M |
| September 30, 2024 | -7.274M |
| June 30, 2024 | -8.928M |
| March 31, 2024 | -12.12M |
| December 31, 2023 | -9.896M |
| September 30, 2023 | -5.184M |
| June 30, 2023 | -9.475M |
| Date | Value |
|---|---|
| March 31, 2023 | -8.139M |
| December 31, 2022 | -7.276M |
| September 30, 2022 | -5.386M |
| June 30, 2022 | 6.136M |
| March 31, 2022 | -15.65M |
| December 31, 2021 | -14.36M |
| September 30, 2021 | -15.20M |
| June 30, 2021 | -10.53M |
| March 31, 2021 | -12.55M |
| December 31, 2020 | 20.59M |
| September 30, 2020 | -21.94M |
| June 30, 2020 | -12.80M |
| March 31, 2020 | -8.733M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Precigen, Inc. | -17.81M |
| Agenus, Inc. | -31.20M |
| Amgen, Inc. | 4.002B |
| Anika Therapeutics, Inc. | -0.684M |
| BioCryst Pharmaceuticals, Inc. | 103.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 16.51M |
| Free Cash Flow | -37.71M |
| Free Cash Flow Per Share (Quarterly) | -0.4243 |
| Free Cash Flow to Equity (Quarterly) | -7.973M |
| Free Cash Flow to Firm (Quarterly) | -7.755M |
| Free Cash Flow Yield | -73.82% |